Pharmaprogress opening
29 Dec 17

Opening Event at Pharmaprogress laboratories

On December 19, the Mayor of Camerata Picena Mr. Paolo Tittarelli, inagurated the refurbished facilities of Pharmaprogress in Ancona (Italy). An important investment plan has been executed after the Pharmaprogress acquisition by Kymos in November 2016. The refurbishement has been focused in electric supply lines, power generator, data center, LAN and laboratory benches. In addition, during this first year new HPLCs, balances, and other instruments have been acquired. The visit of the Mayor finished with a Christmas cellebration with employees and partners.


Immunogenicity study communication
28 Nov 17

KYMOS communication in the 10th EBF Symposium

Kymos presented an oral communication on the immunogenicity of gonadotrophines used for ovarian stimulation, during the 10th EBF Open Symposium held past 15-17 November 2017 in Barcelona. Kymos' Immunology Manager, Dr. Carles Morte, shared with the attendees the bioanalytical strategy followed and the results of two clinical studies. This work was done in collaboration with IBSA (Switzerland), the University of Basel (Switzerland), the Semmelweis University (Budapest, Hungary) and the Institut Universitari Dexeus (Barcelona, Spain).

FDA logo
20 Nov 17

FDA recognizes 8 European Agencies for inspections

The U.S. Food and Drug Administration has determined the agency will recognize eight European drug regulatory authorities as capable of conducting inspections of manufacturing facilities that meet FDA requirements. The eight regulatory authorities found to be capable are those located in: Austria, Croatia, France, Italy, Malta, Spain, Sweden and the United Kingdom.

Kymos stand at CPhI 2017 in Frankfurt
30 Oct 17

Kymos in the CPhI 2017 in Frankfurt

KYMOS and its Italian affiliate PHARMAPROGRESS have particIpated in the Worldwide CPhI 2017 in Frankfurt during October 24-26. The stand was very attended and we had around 80 meeting with current and potencial partners. We thank all our visitors for their interest and friendliness.

17 Sep 17

CRO Market Growth

The global CRO market value is expected to exceed $32 billion in 2017 and reach $45 billion by 2022, according to a report by Grand View Research, with growth attributed to greater R&D spend, M&A activity, as well as government contracts with CROs. The role of CROs in helping pharma and biopharma firms address today’s complex drug development challenges, has grown considerably these past few years.


Kymos at 5th Antibody Industrial Symposium 2017
28 Jun 17

Kymos in the 5th Antibody Symposium 2017 in Tours, France

KYMOS participates with a booth in the 5th Antibody Industrial Symposium 2017, that takes place on June 27 and 28 in Tours, France. This year the scope of the Symposium is the Antibody-Drug Conjugates. An important pannel of experts presented the last innovations in this field and the new products that will be hopefully marketed in the years to come.

KYMOS and the IFTH
17 Jun 17

Great Success of the "Phase I Clinical Trials in Spain"

KYMOS is a proud to have been the sponsor and coorganizer of the "Phase I Clinical Trials in Spain" Session. The event took place on June 14 in the Barcelona Sicence Park and had a great success with around 100 attendees. KYMOS' CEO, Joan Puig de Dou, welcomed and farewelled the participants. Other KYMOS team members participate during the event: Lluisa Garcia (COO) moderated a roundtable and Jaume Pascual (Scientific Director Small Molecules) and Carles Celma (Scientific Director Biologics) exhibited very interesting scientific presentations.